UroGen Pharma Ltd. Deferred Tax Assets, Other
UroGen Pharma Ltd. (URGN) had Deferred Tax Assets, Other of $2.36 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOther · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Other $2.36M.
- 2024-12-31: Deferred Tax Assets, Other $988.00K.
- 2023-12-31: Deferred Tax Assets, Other $877.00K; Deferred Tax Assets, Other as first filed $875.00K.
- 2022-12-31: Deferred Tax Assets, Other $561.00K.
| Period end | Deferred Tax Assets, Other | Deferred Tax Assets, Other as first filed |
|---|---|---|
| 2025-12-31 | $2.36M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $988.00K 10-K · filed 2026-03-02 | |
| 2023-12-31 | $877.00K 10-K · filed 2025-03-10 | $875.00K 10-K · filed 2024-03-14 |
| 2022-12-31 | $561.00K 10-K · filed 2024-03-14 | |
| 2021-12-31 | $319.00K 10-K · filed 2023-03-24 | |
| 2020-12-31 | $18.00K 10-K · filed 2022-03-21 | |
| 2019-12-31 | $62.00K 10-K · filed 2021-03-18 | |
| 2018-12-31 | $84.00K 10-K · filed 2020-03-02 | |
| 2017-12-31 | $24.00K 10-K · filed 2020-03-02 | |
| 2016-12-31 | $72.00K 10-K · filed 2019-02-28 | |
| 2015-12-31 | $66.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |